Every clinical trial provides new insight into tumor biology and optimal patient care. Illustrated are pivotal trials across five gastrointestinal tumors, representing a multitude of mechanistic approaches in different treatment settings—some successful, some unsuccessful, but all informative. Most recently, a wave of immune checkpoint inhibitor-based approaches has provided new options to patients, with the notable exception of pancreatic cancer. Additionally, for many of these tumors, no branded options have had success in early-stage disease, leading to continuing unmet need.

Contact Cerner Enviza to explore how these historical trends have shaped the trial landscape over time and how they can provide direction for future developmental strategies.

Trials are those tracked in the CancerMPact® Future Trends and Insights module that either failed or have culminated in an FDA approval as of July 25th, 2022. Failed trials and FDA approvals are shown in the year they were announced.

**Settings**
- Neo-adjuvant/Low risk, Resectable
- Locally advanced, Resectable
- Metastatic, Advanced
- Second line, Metastatic

**Cerner Enviza**

Cerner Enviza aims to accelerate the discovery, development and delivery of extraordinary insights and therapies to improve everyday health for all people globally. By combining decades of innovation, life sciences knowledge and collaboration research, Cerner Enviza provides data-driven solutions and expertise that help bring remarkable clarity to healthcare's most important decisions.

For more information on Cerner Enviza, visit info@cernerenviza.com. For more information, please contact www.cernerenviza.com.

Copyright © 2022 Oracle and/or its affiliates. All rights reserved. 2793948912 Cerner Enviza infographic on trials in gastro-intestinal cancers v1/August 2022